{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:37:49Z","timestamp":1788435469620,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Prurigo nodularis (PN) is characterized by intensely itchy nodules\/lesions and skin pain, which can have a substantial impact on health\u2010related quality of life (HRQoL). Treatment benefits on such symptoms and impacts are best assessed in trials using patient\u2010reported outcome (PROs) instruments such as Skin Pain Numerical Rating Scale (NRS), Sleep\u2010NRS and Dermatology Life Quality Index (DLQI). However, no guidance exists for interpreting meaningful changes in scores using these PROs in patients with PN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The main objective was to derive within\u2010patient (responder definition) and between\u2010group improvement thresholds for interpreting Skin Pain\u2010NRS, Sleep\u2010NRS and DLQI total scores in patients with PN. The measurement properties of the three PROs were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Intention\u2010to\u2010treat (ITT), blinded and pooled data were used from the Phase 3 PRIME (NCT04183335) and PRIME2 (NCT04202679) studies evaluating the efficacy of dupilumab in adult patients with PN. Anchor\u2010 and distribution\u2010based methods were applied to derive responder definition and between\u2010group thresholds for Skin Pain\u2010NRS, Sleep\u2010NRS and DLQI. Data were additionally used to examine the instrument measurement properties, including reliability, validity and responsiveness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 311 patients (mean age 49.5\u2009years, 65.3% female) were included in the pooled ITT population. The within\u2010patient improvement threshold for Skin Pain\u2010NRS was estimated as 4.0 points, 2.0 points for Sleep\u2010NRS and 9.0 points for DLQI total score. A 1.5\u2010point improvement in Skin Pain\u2010NRS scores, 1.0\u2010point in Sleep\u2010NRS and 4.0\u2010point in DLQI indicated a between\u2010group meaningful change. Adequate to good psychometric properties were demonstrated for all three instruments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results of this study can aid interpretation of Skin Pain\u2010NRS, Sleep\u2010NRS and DLQI scores in patients with PN in both clinical trials and clinical practice to better understand and treat PN\u2010related skin pain and the impact of PN on sleep quality and HRQoL.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.19800","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T13:10:46Z","timestamp":1707397846000},"page":"1401-1409","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Estimating meaningful change thresholds for Skin Pain\u2010Numeric Rating Scale, Sleep\u2010Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"S.","family":"Stander","sequence":"first","affiliation":[{"name":"University Clinic M\u00fcnster  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Guillemin","sequence":"additional","affiliation":[{"name":"IQVIA  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rhoten","sequence":"additional","affiliation":[{"name":"IQVIA  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wratten","sequence":"additional","affiliation":[{"name":"IQVIA  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Brookes","sequence":"additional","affiliation":[{"name":"Sanofi  Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. T.","family":"O'Malley","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-6486","authenticated-orcid":false,"given":"A.","family":"Bansal","sequence":"additional","affiliation":[{"name":"Regeneron  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Msihid","sequence":"additional","affiliation":[{"name":"Sanofi  Gentilly France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Regeneron  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9887-8159","authenticated-orcid":false,"given":"D.","family":"Bahloul","sequence":"additional","affiliation":[{"name":"Sanofi  Gentilly France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2774"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.052"},{"key":"e_1_2_10_4_1","unstructured":"National Institute of Health.Prurigo nodularis. 2018 [cited 2023 Apr 5]. Available from:https:\/\/rarediseases.info.nih.gov\/diseases\/7480\/prurigo\u2010nodularis"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15107"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16929"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2015.07.010"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.044"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13827"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13491"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_10_12_1","unstructured":"Food and Drug Administration.Guidance for industry patient\u2010reported outcome measures: use in medical product development to support labeling claims. 2009 [cited 2023 Apr 5]. Available from:https:\/\/www.fda.gov\/media\/77832\/download"},{"key":"e_1_2_10_13_1","unstructured":"Food and Drug Administration.Patient\u2010focused drug development guidance public workshop: incorporating clinical outcome assessments into endpoints for regulatory decision\u2010making. 2019 [cited 2023 Apr 5]. Available from:https:\/\/www.fda.gov\/media\/132505\/download"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-021-02957-4"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17111"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08832.x"},{"key":"e_1_2_10_17_1","unstructured":"Cardiff University Department of Dermatology.Dermatology Life Quality Index. 2019 [cited 2023 Apr 5]. Available from:https:\/\/www.cardiff.ac.uk\/medicine\/resources\/quality\u2010of\u2010life\u2010questionnaires\/dermatology\u2010life\u2010quality\u2010index"},{"key":"e_1_2_10_18_1","unstructured":"EMA.Reflection paper on the regulatory guidance for the use of health\u2010related quality of life (Hrql) measures in the evaluation of medicinal products. 2005 [cited 2023 Apr 5]. Available from:https:\/\/www.ema.europa.eu\/en\/regulatory\u2010guidance\u2010use\u2010health\u2010related\u2010quality\u2010life\u2010hrql\u2010measures\u2010evaluation\u2010medicinal\u2010products"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.012"},{"key":"e_1_2_10_20_1","first-page":"25","article-title":"Reliability and validity (including reponsiveness). Assessing quality of life in clinical trials","volume":"2","author":"Revicki DA","year":"2005","journal-title":"Methods Practice"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcm.2016.02.012"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02288892"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050663"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3048"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-71"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T13:14:00Z","timestamp":1731590040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/jdv.19800"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19800","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"2023-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}